David Michael C B, Mallas Emma-Jane, Li Lucia M, Kolanko Magdalena A, Nilforooshan Ramin, Tsoi Man Lai, Karakoc Hanim, Hoang Karen, Brandt Johanna, Triantafyllou Charikleia, Gruia Dragos C, Custovic Darije, Lally Peter J, Zimmerman Karl A, Malhotra Paresh A, Scott Gregory, Sharp David J
UK Dementia Research Institute Care Research and Technology Centre, Imperial College London, London W12 0BZ, UK.
Imperial College London, Brain Sciences, South Kensington, London SW7 2AZ, UK.
Brain Commun. 2025 Jul 22;7(4):fcaf236. doi: 10.1093/braincomms/fcaf236. eCollection 2025.
Arousal dysfunction contributes to impairments seen in Alzheimer's disease. However, the nature and degree of this dysfunction have not been studied in detail. We investigated changes in tonic and phasic arousal using simultaneous pupillometry-EEG, relating these changes to locus coeruleus integrity, a key arousal nucleus. Forty Alzheimer's disease participants and 30 controls underwent neuropsychological testing using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), MRI designed to show contrast in the locus coeruleus as a measure of integrity and simultaneous pupillometry-EEG during 5 min of eyes-open resting-state. Pupillometry-EEG was then also applied during an oddball task which included a passive session and sessions in which responses to target stimuli were required, to test the effect of salience. Alzheimer's disease had lower locus coeruleus integrity ( = -0.26, = 0.02) and lower peak alpha frequency (tonic arousal) ( = -1.09, < 0.001). Both were related to ADAS-Cog. There was a very strong relationship between pupil size and both periodic and aperiodic EEG power. Cortical slowing in Alzheimer's disease affected this relationship, particularly at low frequencies. During the attentionally demanding oddball task, Alzheimer's disease participants' behavioural performance was impaired, with reduced accuracy and slower and more variable reaction times. They also had reduced pupil responses to salient stimuli (phasic arousal) (estimate = -0.19, < 0.001). EEG and pupil measures of pre-stimulus tonic arousal were strongly correlated and predicted behavioural responses in both groups. Arousal fluctuations at rest and in response to stimuli are abnormal in Alzheimer's disease as measured by combined pupillometry and EEG. Salient stimuli that require a behavioural response are accompanied by a phasic increase in arousal, demonstrated by pupil dilation to oddball stimuli. This response is slower and of smaller magnitude in Alzheimer's disease patients. Cortical slowing (reduced peak alpha frequency) is seen in Alzheimer's disease, and this is modulated by arousal level and relates to overall cognition. Pupil-linked arousal responses and alpha EEG fluctuations are tightly coupled, but cortical slowing in Alzheimer's disease influences this coupling. The tools used here to measure neurophysiological arousal level have potential in understanding the nature of arousal system dysfunction in Alzheimer's disease at the group level. These tools may also be used as biomarkers at the individual level in order to target patients most likely to benefit from arousal-modulating medications.
觉醒功能障碍是阿尔茨海默病中出现的损害的一个原因。然而,这种功能障碍的性质和程度尚未得到详细研究。我们使用同步瞳孔测量-脑电图来研究紧张性和相位性觉醒的变化,并将这些变化与蓝斑完整性(一个关键的觉醒核团)联系起来。40名阿尔茨海默病参与者和30名对照者接受了使用阿尔茨海默病评估量表-认知子量表(ADAS-Cog)的神经心理学测试、旨在显示蓝斑对比度以衡量其完整性的MRI以及在5分钟睁眼静息状态下的同步瞳孔测量-脑电图。然后在一个包含被动环节和需要对目标刺激做出反应的环节的oddball任务中也应用了瞳孔测量-脑电图,以测试显著性的影响。阿尔茨海默病患者的蓝斑完整性较低(β = -0.26,P = 0.02),峰值阿尔法频率(紧张性觉醒)也较低(β = -1.09,P < 0.001)。两者均与ADAS-Cog相关。瞳孔大小与周期性和非周期性脑电图功率之间存在非常强的关系。阿尔茨海默病中的皮层减慢影响了这种关系,尤其是在低频时。在注意力要求较高的oddball任务中,阿尔茨海默病参与者的行为表现受损,准确性降低,反应时间更慢且更具变异性。他们对显著刺激(相位性觉醒)的瞳孔反应也降低(估计值 = -0.19,P < 0.001)。刺激前紧张性觉醒的脑电图和瞳孔测量指标密切相关,并预测了两组的行为反应。通过联合瞳孔测量和脑电图测量发现,阿尔茨海默病患者在静息状态和对刺激的反应中的觉醒波动是异常的。需要行为反应的显著刺激会伴随着觉醒的相位性增加,表现为对oddball刺激的瞳孔扩张。在阿尔茨海默病患者中,这种反应更慢且幅度更小。阿尔茨海默病中可见皮层减慢(峰值阿尔法频率降低),这受到觉醒水平的调节并与整体认知相关。与瞳孔相关的觉醒反应和阿尔法脑电图波动紧密耦合,但阿尔茨海默病中的皮层减慢会影响这种耦合。这里用于测量神经生理觉醒水平的工具在理解阿尔茨海默病中觉醒系统功能障碍的性质方面具有群体层面的潜力。这些工具也可在个体层面用作生物标志物,以便针对最可能从觉醒调节药物中受益的患者。
Brain Commun. 2025-7-22
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2003
Cochrane Database Syst Rev. 2021-2-22
Cochrane Database Syst Rev. 2002
Cochrane Database Syst Rev. 2001
Cochrane Database Syst Rev. 2001
Cochrane Database Syst Rev. 2024-11-5
Wiley Interdiscip Rev Cogn Sci. 2024
Curr Biol. 2023-11-20